CoChat
Sign Up
Cited by 554Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsCardiac pacing and defibrillation studies

2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction

Open access
Kittleson, Michelle M., Panjrath, Gurusher S., Amancherla, Kaushik, Davis, Leslie L., Deswal, Anita, Dixon, Dave L., Januzzi, James L., Yancy, Clyde W.·2023·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2023.03.393
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2023.03.393

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • People with diabetes may present with a wide spectrum of heart failure, including HFpEF, HFmrEF, or HFrEF.

    “People with diabetes may present with a wide spectrum of heart failure, including heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), or heart failure with reduced ejection fraction (HFrEF) (12,13).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [13]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 203

  1. [1]1. Januzzi J.L. Jr., Ahmad T., Binder L.G., et al. 2019 methodology for creating expert consensus decision pathways: a report of the American College of Cardiology. J Am Coll Cardiol. 2019;74:1138-1150. Go to Citation Crossref PubMed Google Scholar
  2. [2]2. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072. Crossref PubMed Google Scholar a [...] risk at age 40 years of approximately 20%. b [...] increasing to nearly 30% by age 55 years.
  3. [3]3. Gerber Y., Weston S.A., Redfield M.M., et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175:996-1004. Go to Citation Crossref PubMed Google Scholar
  4. [4]4. Tsao C.W., Lyass A., Enserro D., et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. J Am Coll Cardiol HF. 2018;6:678-685. Go to Citation Google Scholar
  5. [5]5. Virani S.S., Alonso A., Benjamin E.J., et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139-e596. Go to Citation Crossref PubMed Google Scholar
  6. [6]6. Shah K.S., Xu H., Matsouaka R.A., et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476-2486. Crossref PubMed Google Scholar a [...] with reduced ejection fraction (HFrEF). b [...] DELIVER
  7. [7]7. Bozkurt B., Coats A.J., Tsutsui H., et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. Published online February 7, 2021. https://doi.org/10.1016/j.cardfail.2021.01.022. Google Scholar a [...] pulmonary or systemic congestion. b [...] by the Universal Definition of HF, c [...] the Universal Definition of Heart Failure d [...] includes HFpEF-specific considerations). e [...] is from HF, the Universal Definition of HF f [...] EMPEROR-PRESERVED · DOI
  8. [8]8. Abraham W.T., Psotka M.A., Fiuzat M., et al. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. J Am Coll Cardiol HF. 2020;8:961-972. Go to Citation Google Scholar
  9. [9]9. Chung A.K., Das S.R., Leonard D., et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation. 2006;113:1597-1604. Go to Citation Crossref PubMed Google Scholar
  10. [10]10. Sugimoto T., Dulgheru R., Bernard A., et al. Echocardiographic reference ranges for normal left ventricular 2d strain: results from the EACVI NORRE study. Eur Heart J Cardiovasc Imaging. 2017;18:833-840. Go to Citation Crossref PubMed Google Scholar
  11. [11]11. Mohebi R., Chen C., Ibrahim N.E., et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. J Am Coll Cardiol. 2022;80:565-578. Go to Citation Crossref PubMed Google Scholar
  12. [12]12. Williams D., Stout M.J., Rosenbloom J.I., et al. Preeclampsia predicts risk of hospitalization for heart failure with preserved ejection fraction. J Am Coll Cardiol. 2021;78:2281-2290. Go to Citation Crossref PubMed Google Scholar
  13. [13]13. Morris P.B., Kovacs R.J., Allen L.A., et al. 2019 methodology for heart house roundtables: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019;74:1116-1137. Go to Citation Crossref PubMed Google Scholar
  14. [14]14. Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263-e421. Crossref PubMed Google Scholar a [...] (HFSA) Guideline for the Management of HF. b [...] Clinical diagnosis of HF and LVEF ≤40%. c [...] diagnosis of HF and LVEF 41% to 49%. d [...] : Clinical diagnosis of HF and LVEF ≥50% e [...] morbidity and mortality associated with HF f [...] therapy from clinical practice guidelines, g [...] in the 2022 AHA/ACC/HFSA HF Guidelines, h [...] to reduce congestion and improve symptoms. i [...] potential for chronotropic incompetence. j [...] and treatment of relevant comorbidities k [...] 2b recommendation for remote PA monitoring. l [...] contraindicated in individuals with HFpEF. m [...] for the mitigation of thromboembolic risk. n [...] in HFpEF with a Class 3 recommendation. o [...] may be considered for polysomnography. p [...] improve sleep quality and quality of life. q [...] Guideline for the Management of HF. r [...] preventing, and treating suffering.
  15. [15]15. Hicks K.A., Tcheng J.E., Bozkurt B., et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66:403-469. Go to Citation Crossref PubMed Google Scholar
  16. [16]16. McKee P.A., Castelli W.P., McNamara P.M., et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446. Crossref PubMed Google Scholar a [...] during the Framingham Heart Study. b [...] TOPCAT
  17. [17]17. Anjan V.Y., Loftus T.M., Burke M.A., et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:870-876. Crossref PubMed Google Scholar a [...] invasive hemodynamic evidence of HF. b [...] without obesity, particularly in HFpEF c [...] measured cardiac filling pressures,
  18. [18]18. Kelly A.M., Keijzers G., Klim S., et al. Epidemiology and outcome of older patients presenting with dyspnoea to emergency departments. Age Ageing. 2021;50:252-257. Go to Citation Crossref PubMed Google Scholar
  19. [19]19. Logeart D., Saudubray C., Beyne P., et al. Comparative value of doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol. 2002;40:1794-1800. Crossref PubMed Google Scholar a [...] hospitalizations across the spectrum of age b [...] PARAGON-HF c [...] HF With Preserved Ejection Fraction) trial,
  20. [20]20. Ramalho S.H.R., Santos M., Claggett B., et al. Association of undifferentiated dyspnea in late life with cardiovascular and noncardiovascular dysfunction: a cross-sectional analysis from the ARIC study. JAMA Netw Open. 2019;2:e195321. Go to Citation Crossref PubMed Google Scholar
  21. [21]21. Wang C.S., FitzGerald J.M., Schulzer M., et al. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294:1944-1956. Go to Citation Crossref PubMed Google Scholar
  22. [23]23. Goss J.A., Greene A.K. Sensitivity and specificity of the stemmer sign for lymphedema: a clinical lymphoscintigraphic study. Plast Reconstr Surg Glob Open. 2019;7:e2295. Go to Citation Crossref PubMed Google Scholar
  23. [24]24. Jayaraj A., Raju S., May C., et al. The diagnostic unreliability of classic physical signs of lymphedema. J Vasc Surg Venous Lymphat Disord. 2019;7:890-897. Crossref PubMed Google Scholar a [...] may cause a false-positive Stemmer sign. b [...] CHARM-PRESERVED
  24. [25]25. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. Crossref PubMed Google Scholar a [...] diagnostic evaluation of suspected HFpEF. b [...] of 60% to 89% in the HFpEF population.
  25. [26]26. Redfield M.M. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375:1868-1877. Go to Citation Crossref PubMed Google Scholar
  26. [27]27. Reddy Y.N.V., Carter R.E., Obokata M., et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861-870. Crossref PubMed Google Scholar a [...] diagnostic evaluation of suspected HFpEF. b [...] (E/e’ >9 on Doppler echocardiography).
  27. [28]28. Pieske B., Tschope C., de Boer R.A., et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:391-412. Crossref PubMed Google Scholar a [...] diagnostic evaluation of suspected HFpEF. b [...] including potential hemodynamic assessment
  28. [29]29. Khalid U., Wruck L.M., Quibrera P.M., et al. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: the Atherosclerosis Risk In Communities Surveillance Study. Int J Cardiol. 2017;233:61-66. Crossref PubMed Google Scholar a [...] with HFpEF compared with those with HFrEF, b [...] without obesity, particularly in HFpEF c [...] measured cardiac filling pressures, d [...] are either overweight or have obesity.
  29. [30]30. Obokata M., Reddy Y.N.V., Pislaru S.V., et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6-19. Crossref PubMed Google Scholar a [...] without obesity, particularly in HFpEF b [...] and heightened ventricular interdependence. c [...] related to the amount of excess body mass.
  30. [31]31. Singh S., Pandey A., Neeland I.J. Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure. Prog Cardiovasc Dis. 2020;63:649-655. Go to Citation Crossref PubMed Google Scholar
  31. [32]32. Frankenstein L., Remppis A., Nelles M., et al. Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J. 2008;29:2634-2640. Go to Citation Crossref PubMed Google Scholar
  32. [33]33. Mueller C., McDonald K., de Boer R.A., et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715-731. Go to Citation Crossref PubMed Google Scholar
  33. [34]34. van Riet E.E., Hoes A.W., Wagenaar K.P., et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18:242-252. Go to Citation Crossref PubMed Google Scholar
  34. [35]35. Iyngkaran P., Majoni W., Cass A., et al. Northern territory perspectives on heart failure with comorbidities – understanding trial validity and exploring collaborative opportunities to broaden the evidence base. Heart Lung Circ. 2015;24:536-543. Go to Citation Crossref PubMed Google Scholar
  35. [36]36. Mentz R.J., Kelly J.P., von Lueder T.G., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281-2293. Go to Citation Crossref PubMed Google Scholar
  36. [37]37. Selvaraj S., Myhre P.L., Vaduganathan M., et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. J Am Coll Cardiol HF. 2020;8:640-653. Go to Citation Google Scholar
  37. [38]38. Sanders-van Wijk S., Barandiaran Aizpurua A., Brunner-La Rocca H.P., et al. The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:838-840. Go to Citation Crossref PubMed Google Scholar
  38. [39]39. Reddy Y.N.V., Kaye D.M., Handoko M.L., et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol. 2022;7:891-899. Go to Citation Crossref PubMed Google Scholar
  39. [40]40. Tibrewala A., Yancy C.W. Heart failure with preserved ejection fraction in women. Heart Fail Clin. 2019;15:9-18. Go to Citation Crossref PubMed Google Scholar
  40. [41]41. Sotomi Y., Hikoso S., Nakatani D., et al. Sex differences in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10:e018574. Go to Citation Crossref Google Scholar
  41. [42]42. Cediel G., Codina P., Spitaleri G., et al. Gender-related differences in heart failure biomarkers. Front Cardiovasc Med. 2020;7:617705. Go to Citation PubMed Google Scholar
  42. [43]43. Kittleson M.M., Maurer M.S., Ambardekar A.V., et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7-e22. Go to Citation Crossref PubMed Google Scholar
  43. [44]44. Kittleson M.M., Ruberg F.L., Ambardekar A.V., et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81:1076-1126. Go to Citation Crossref PubMed Google Scholar
  44. [45]45. Oghina S., Bougouin W., Bézard M., et al. The impact of patients with cardiac amyloidosis in HFpEF trials. J Am Coll Cardiol HF. 2021;9:169-178. Go to Citation Google Scholar
  45. [46]46. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345. Crossref PubMed Google Scholar a [...] in HFpEF, including trials of perindopril, b [...] adults (aged ≥70 years) and LVEF >40%. c [...] ARNIs, ARBs, and MRAs (as outlined in
  46. [48]48. Fonarow G.C., Abraham W.T., Albert N.M., et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168:847-854. Crossref PubMed Google Scholar a [...] beta-blockers, b [...] is a key therapeutic strategy in HFpEF,
  47. [49]49. Hernandez A.F., Hammill B.G., O'Connor C.M., et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184-192. Go to Citation Crossref PubMed Google Scholar
  48. [50]50. Redfield M.M., Anstrom K.J., Levine J.A., et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373:2314-2324. Crossref PubMed Google Scholar a [...] nitrates, b [...] With Preserved Ejection Fraction) trial.
  49. [51]51. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403. Go to Citation Crossref PubMed Google Scholar
  50. [52]52. Komajda M., Isnard R., Cohen-Solal A., et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495-1503. Go to Citation Crossref PubMed Google Scholar
  51. [53]53. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277. Go to Citation Crossref PubMed Google Scholar
  52. [55]55. Bhagat A.A., Greene S.J., Vaduganathan M., et al. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. J Am Coll Cardiol HF. 2019;7:1-12. Go to Citation Google Scholar
  53. [56]56. Hollenberg S.M., Warner Stevenson L., Ahmad T., et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019;74:1966-2011. Crossref PubMed Google Scholar a [...] in both acute and chronic-care settings. b [...] escalate, and psychosocial factors. c [...] Adapted from Hollenberg et al.
  54. [58]58. Fihn S.D., Gardin J.M., Abrams J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44-e164. Go to Citation Crossref PubMed Google Scholar
  55. [61]61. Anker S.D., Butler J., Filippatos G., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. Crossref PubMed Google Scholar a [...] now confirmed in 2 randomized trials, b [...] Failure with Preserved Ejection Fraction) c [...] of life regardless of the presence of T2DM, d [...] with the SGLT2i empagliflozin vs placebo.
  56. [62]62. Kosiborod M.N., Bhatt A.S., Claggett B.L., et al. Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol. 2023;81:460-473. Go to Citation Crossref PubMed Google Scholar
  57. [63]63. Nassif M.E., Windsor S.L., Borlaug B.A., et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954-1960. Go to Citation Crossref PubMed Google Scholar
  58. [64]64. Verma S., Dhingra N.K., Butler J., et al. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022;10:35-45. Go to Citation Crossref PubMed Google Scholar
  59. [65]65. Ferreira J.P., Zannad F., Pocock S.J., et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77:1397-1407. Go to Citation Crossref PubMed Google Scholar
  60. [66]66. Voors A.A., Angermann C.E., Teerlink J.R., et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568-574. Go to Citation Crossref PubMed Google Scholar
  61. [67]67. Biegus J., Voors A.A., Collins S.P., et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023;44:1: 41-50. Go to Citation Crossref PubMed Google Scholar
  62. [68]68. Kosiborod M.N., Angermann C.E., Collins S.P., et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation. 2022;146:279-288. Go to Citation Crossref PubMed Google Scholar
  63. [69]69. Packer M., Butler J., Zannad F., et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021;144:1284-1294. Crossref PubMed Google Scholar a [...] with EFs of >40% to <50% and 50% to <60%. b [...] of life regardless of the presence of T2DM,
  64. [70]70. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the ALDO-DHF randomized controlled trial. JAMA. 2013;309:781-791. Crossref PubMed Google Scholar a [...] function in individuals with HFpEF. b [...] tolerance in individuals with HFpEF,
  65. [71]71. Pitt B., Pfeffer M.A., Assmann S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. Crossref PubMed Google Scholar a [...] function in individuals with HFpEF. b [...] hyperkalemia and worsening kidney function. c [...] with an Aldosterone Antagonist) trial d [...] ARNIs, ARBs, and MRAs (as outlined in
  66. [72]72. Pfeffer M.A., Claggett B., Assmann S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34-42. Crossref PubMed Google Scholar a [...] (HR: 1.10; 95% CI: 0.79-1.51). b [...] ARNIs, ARBs, and MRAs (as outlined in
  67. [73]73. de Denus S., O'Meara E., Desai A.S., et al. Spironolactone metabolites in TOPCAT - new insights into regional variation. N Engl J Med. 2017;376:1690-1692. Go to Citation Crossref PubMed Google Scholar
  68. [74]74. Anand I.S., Claggett B., Liu J., et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. J Am Coll Cardiol HF. 2017;5:241-252. Go to Citation Google Scholar
  69. [75]75. Solomon S.D., Claggett B., Lewis E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-462. Go to Citation Crossref PubMed Google Scholar
  70. [76]76. Merrill M., Sweitzer N.K., Lindenfeld J., et al. Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. J Am Coll Cardiol HF. 2019;7:228-238. Google Scholar a [...] and in women, b [...] as well as spironolactone
  71. [77]77. Solomon S.D., McMurray J.J.V., Anand I.S., et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-1620. Crossref PubMed Google Scholar a [...] rare, occur more frequently with ARNIs. b [...] ARNIs, ARBs, and MRAs (as outlined in
  72. [78]78. Vaduganathan M., Claggett B.L., Desai A.S., et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol. 2020;75:245-254. Go to Citation Crossref PubMed Google Scholar
  73. [79]79. McMurray J.J.V., Jackson A.M., Lam C.S.P., et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020;141:338-351. Crossref PubMed Google Scholar a [...] with men (HR: 1.03; 95% CI: 0.84-1.25). b [...] the use of sacubitril/valsartan
  74. [81]81. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777-781. Crossref PubMed Google Scholar a [...] in Mortality and Morbidity)-Preserved trial b [...] ARNIs, ARBs, and MRAs (as outlined in
  75. [82]82. Addetia K., Miyoshi T., Amuthan V., et al. Normal values of left ventricular size and function on three-dimensional echocardiography: results of the World Alliance Societies of Echocardiography Study. J Am Soc Echocardiogr. 2022;35:449-459. Go to Citation Crossref PubMed Google Scholar
  76. [84]84. Edelmann F., Gelbrich G., Düngen H.D., et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol. 2011;58:1780-1791. Go to Citation Crossref PubMed Google Scholar
  77. [85]85. Mueller S., Winzer E.B., Duvinage A., et al. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2021;325:542-551. Crossref PubMed Google Scholar a [...] Mueller et al b [...] capacity in individuals with HFpEF.
  78. [88]88. Brubaker P.H., Nicklas B.J., Houston D.K., et al. A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction. Circ Heart Fail. 2023;16:e010161. Crossref PubMed Google Scholar a [...] Brubaker et al b [...] restriction improved leg muscle strength,
  79. [90]90. Abraham W.T., Adamson P.B., Bourge R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-666. Crossref PubMed Google Scholar a [...] Adamson et al b [...] significantly reduced HF hospitalizations,
  80. [91]91. Adamson P.B., Abraham W.T., Bourge R.C., et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935-944. Crossref PubMed Google Scholar a [...] Adamson et al b [...] of study participants with LVEF ≥40%.
  81. [92]92. Lindenfeld J., Zile M.R., Desai A.S., et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398:991-1001. Crossref PubMed Google Scholar a [...] Lindenfeld et al b [...] peptides; 31% had an LVEF of 50% or higher.
  82. [93]93. Pandey A., LaMonte M., Klein L., et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017;69:1129-1142. Go to Citation Crossref PubMed Google Scholar
  83. [94]94. Aune D., Sen A., Norat T., et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation. 2016;133:639-649. Go to Citation Crossref PubMed Google Scholar
  84. [96]96. Brinker S.K., Pandey A., Ayers C.R., et al. Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the Cooper Center Longitudinal Study. J Am Coll Cardiol HF. 2014;2:238-246. Go to Citation Google Scholar
  85. [97]97. Persson C.E., Bjorck L., Lagergren J., et al. Risk of heart failure in obese patients with and without bariatric surgery in Sweden-a registry-based study. J Card Fail. 2017;23:530-537. Go to Citation Crossref PubMed Google Scholar
  86. [98]98. Rider O.J., Francis J.M., Ali M.K., et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol. 2009;54:718-726. Go to Citation Crossref PubMed Google Scholar 98a. Arnett D.K., Blumenthal R.S., Albert M.A., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:e177-e232. Go to Citation Crossref PubMed Google Scholar
  87. [99]99. Pandey A., Parashar A., Kumbhani D., et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8:33-40. Go to Citation Crossref PubMed Google Scholar
  88. [100]100. Kitzman D.W., Whellan D.J., Duncan P., et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med. 2021;385:203-216. Go to Citation Crossref PubMed Google Scholar
  89. [101]101. Kamiya K., Sato Y., Takahashi T., et al. Multidisciplinary cardiac rehabilitation and long-term prognosis in patients with heart failure. Circ Heart Fail. 2020;13:e006798. Go to Citation Crossref PubMed Google Scholar
  90. [102]102. Gevaert A.B., Kataria R., Zannad F., et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022;108:1342-1350. Go to Citation Crossref PubMed Google Scholar 102a. Sachdev V., Sharma K., Keteyian S.J., et al. Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. Published online March 21, 2023. 10.1016/j.jacc.2023.02.012. Go to Citation Crossref PubMed Google Scholar · DOI
  91. [103]103. Shavelle D.M., Desai A.S., Abraham W.T., et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the cardioMEMS Post-Approval Study. Circ Heart Fail. 2020;13:e006863. Go to Citation Crossref PubMed Google Scholar
  92. [104]104. Zile M.R., Desai A.S., Costanzo M.R., et al. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. Eur Heart J. 2022;43:2603-2618. Go to Citation Crossref PubMed Google Scholar
  93. [105]105. Feldman T., Mauri L., Kahwash R., et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients with Heart Failure]): a phase 2, randomized, sham-controlled trial. Circulation. 2018;137:364-375. Go to Citation Crossref PubMed Google Scholar
  94. [106]106. Shah S.J., Feldman T., Ricciardi M.J., et al. One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol. 2018;3:968-977. Go to Citation Crossref PubMed Google Scholar
  95. [107]107. Shah S.J., Borlaug B.A., Chung E.S., et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet. 2022;399:1130-1140. Go to Citation Crossref PubMed Google Scholar
  96. [108]108. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-e248. Crossref PubMed Google Scholar a [...] management of high blood pressure in adults b [...] of 60% to 89% in the HFpEF population. c [...] a systolic blood pressure <130 mm Hg. d [...] at high risk for cardiovascular disease. e [...] and hypertension,
  97. [109]109. Das S.R., Everett B.M., Birtcher K.K., et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76:1117-1145. Crossref PubMed Google Scholar a [...] for CV risk reduction in patients with T2DM b [...] risk for ASCVD or with pre-existing ASCVD.
  98. [110]110. ElSayed N.A., Aleppo G., Aroda V.R., et al. Standards of care in diabetes-2023. Diabetes Care. 2023;46:S1-S291. Go to Citation Crossref PubMed Google Scholar
  99. [111]111. January C.T., Wann L.S., Calkins H., et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104-132. Crossref PubMed Google Scholar a [...] for the management of patients with AF b [...] from the ACC/AHA guidelines for AF. c [...] for the mitigation of thromboembolic risk.
  100. [112]112. Lawton J.S., Tamis-Holland J.E., Bangalore S., et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21-e129. Crossref PubMed Google Scholar a [...] for coronary artery revascularization, b [...] guided by the relevant ACC/AHA guidelines.
  101. [113]113. Gulati M., Levy P.D., Mukherjee D., et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;78:e187-e285. Go to Citation Crossref PubMed Google Scholar
  102. [116]116. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898. Go to Citation Crossref PubMed Google Scholar
  103. [117]117. Kostis J.B., Davis B.R., Cutler J., et al. SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-216. Go to Citation Crossref PubMed Google Scholar
  104. [118]118. Piller L.B., Baraniuk S., Simpson L.M., et al. Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT). Circulation. 2011;124:1811-1818. Crossref PubMed Google Scholar a [...] and mortality in individuals without HF. b [...] to receive the assigned interventions.
  105. [119]119. Williamson J.D., Supiano M.A., Applegate W.B., et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA. 2016;315:2673-2682. Crossref PubMed Google Scholar a [...] and mortality in individuals without HF. b [...] at high risk for cardiovascular disease.
  106. [121]121. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure—meta-analyses of randomized trials. J Hypertens. 2016;34:373-384.discussion 384. Go to Citation Crossref PubMed Google Scholar
  107. [122]122. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham heart study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119:3070-3077. Go to Citation Crossref PubMed Google Scholar
  108. [123]123. Selvaraj S., Claggett B., Shah S.J., et al. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. Eur J Heart Fail. 2018;20:483-490. Go to Citation Crossref PubMed Google Scholar
  109. [124]124. Selvaraj S., Claggett B.L., Böhm M., et al. Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan. J Am Coll Cardiol. 2020;75:1644-1656. Go to Citation Crossref PubMed Google Scholar
  110. [125]125. Selvaraj S., Vaduganathan M., Claggett B.L., et al. Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER. J Am Coll Cardiol HF. 2023;11:76-89. Go to Citation Google Scholar
  111. [126]126. Kato S., Onishi K., Yamanaka T., et al. Exaggerated hypertensive response to exercise in patients with diastolic heart failure. Hypertens Res. 2008;31:679-684. Go to Citation Crossref PubMed Google Scholar
  112. [127]127. St Gyalai-Korpos I., Tomescu M., Pogorevici A. Hypertensive acute pulmonary oedema as expression of diastolic heart failure. Rom J Intern Med. 2008;46:153-157. Go to Citation PubMed Google Scholar
  113. [129]129. Group S.R., Wright J.T. Jr., Williamson J.D., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116. Crossref PubMed Google Scholar a [...] at high risk for cardiovascular disease. b [...] a component of the primary outcome, by 38%.
  114. [131]131. Minamisawa M., Claggett B., Suzuki K., et al. Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction. Circ Heart Fail. 2021;14:e008293. Go to Citation Crossref PubMed Google Scholar
  115. [132]132. Mandviwala T.M., Basra S.S., Khalid U., et al. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. Int J Obes (Lond). 2020;44:1561-1567. Go to Citation Crossref PubMed Google Scholar
  116. [133]133. Kitzman D.W., Shah S.J. The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol. 2016;68:200-203. Crossref PubMed Google Scholar a [...] are either overweight or have obesity. b [...] skeletal muscle, and exercise tolerance.
  117. [134]134. Mandviwala T.K.U., Deswal A. Obesity and cardiovascular disease: a risk factor or a risk marker? Curr Atheroscler Rep. 2016;18:21. Crossref PubMed Google Scholar a [...] an increased risk for HF hospitalization, b [...] to some extent in HFpEF as in HFrEF.
  118. [135]135. Haass M., Kitzman D.W., Anand I.S., et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324-331. Go to Citation Crossref PubMed Google Scholar
  119. [136]136. Kenchaiah S., Pocock S.J., Wang D., et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart Failure: Assessment of Reduction in Mortality And Morbidity (CHARM) program. Circulation. 2007;116:627-636. Go to Citation Crossref PubMed Google Scholar
  120. [137]137. Khalid U., Ather S., Bavishi C., et al. Pre-morbid body mass index and mortality after incident heart failure: the ARIC study. J Am Coll Cardiol. 2014;64:2743-2749. Go to Citation Crossref PubMed Google Scholar
  121. [138]138. Verbrugge F.H., Borlaug B.A. Heart failure with normal natriuretic peptide levels: More fat, and that is the main problem. Eur Heart J. 2022;43:2248-2249. Go to Citation Crossref PubMed Google Scholar
  122. [139]139. Lavie C.J., McAuley P.A., Church T.S., et al. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol. 2014;63:1345-1354. Go to Citation Crossref PubMed Google Scholar
  123. [140]140. Tsujimoto T., Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70:2739-2749. Go to Citation Crossref PubMed Google Scholar
  124. [142]142. Reddy Y.N.V., Anantha-Narayanan M., Obokata M., et al. Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. J Am Coll Cardiol HF. 2019;7:678-687. Go to Citation Google Scholar
  125. [143]143. Wilding J.P.H., Batterham R.L., Calanna S., et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. Crossref PubMed Google Scholar a [...] loss of over 15 kg over a 68-week period. b [...] loss observed with the GLP1-RA semaglutide
  126. [149]149. McHugh K., DeVore A.D., Wu J., et al. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:602-611. Crossref PubMed Google Scholar a [...] with HFpEF varies from 28% to over 40%. b [...] hypertension, vascular disease, and CKD. c [...] relative risk of all-cause mortality.
  127. [150]150. Lawson C.A., Seidu S., Zaccardi F., et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine. 2021;32:100739. Go to Citation Crossref PubMed Google Scholar
  128. [151]151. Pop-Busui R., Januzzi J.L., Bruemmer D., et al. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022;45:1670-1690. Crossref PubMed Google Scholar a [...] Standards of Medical Care in DM. b [...] therapy in those already on other agents.
  129. [154]154. Castagno D., Baird-Gunning J., Jhund P.S., et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011;162:938-948.e932. Go to Citation Crossref PubMed Google Scholar
  130. [155]155. Turnbull F.M., Abraira C., Anderson R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288-2298. Go to Citation Crossref PubMed Google Scholar
  131. [156]156. ElSayed N.A., Aleppo G., Aroda V.R., et al. 13. Older adults: standards of care in diabetes-2023. Diabetes Care. 2023;46:S216-S229. Go to Citation Crossref PubMed Google Scholar
  132. [157]157. Filippatos G., Butler J., Farmakis D., et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-686. Go to Citation Crossref PubMed Google Scholar
  133. [158]158. Eurich D.T., Weir D.L., Majumdar S.R., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395-402. Go to Citation Crossref PubMed Google Scholar
  134. [159]159. Halabi A., Sen J., Huynh Q., et al. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19:124. Go to Citation Crossref PubMed Google Scholar
  135. [164]164. Dargie H.J., Hildebrandt P.R., Riegger G.A., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol. 2007;49:1696-1704. Go to Citation Crossref PubMed Google Scholar
  136. [165]165. Lipscombe L.L., Gomes T., Levesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634-2643. Go to Citation Crossref PubMed Google Scholar
  137. [166]166. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136. Go to Citation Crossref PubMed Google Scholar
  138. [167]167. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (record): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-2135. Go to Citation Crossref PubMed Google Scholar
  139. [168]168. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108:2941-2948. Go to Citation Crossref PubMed Google Scholar
  140. [169]169. Melenovsky V., Hwang S.J., Redfield M.M., et al. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail. 2015;8:295-303. Go to Citation Crossref PubMed Google Scholar
  141. [170]170. Tsang T.S., Gersh B.J., Appleton C.P., et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636-1644. Go to Citation Crossref PubMed Google Scholar
  142. [171]171. Rosenberg M.A., Gottdiener J.S., Heckbert S.R., et al. Echocardiographic diastolic parameters and risk of atrial fibrillation: the cardiovascular health study. Eur Heart J. 2012;33:904-912. Go to Citation Crossref PubMed Google Scholar
  143. [172]172. Ariyaratnam J.P., Lau D.H., Sanders P., et al. Atrial fibrillation and heart failure: epidemiology, pathophysiology, prognosis, and management. Card Electrophysiol Clin. 2021;13:47-62. Go to Citation Crossref PubMed Google Scholar
  144. [173]173. Zafrir B., Lund L.H., Laroche C., et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-term Registry. Eur Heart J. 2018;39:4277-4284. Crossref PubMed Google Scholar a [...] individuals with HFpEF compared with HFrEF. b [...] in those with HFpEF compared with HFrEF.
  145. [174]174. Santhanakrishnan R., Wang N., Larson M.G., et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133:484-492. Crossref PubMed Google Scholar a [...] individuals with HFpEF compared with HFrEF. b [...] with a 2-fold increase in incident AF.
  146. [175]175. Melenovsky V., Hwang S.J., Lin G., et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3452-3462. Go to Citation Crossref PubMed Google Scholar
  147. [176]176. Mohammed S.F., Hussain I., AbouEzzeddine O.F., et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation. 2014;130:2310-2320. Go to Citation Crossref PubMed Google Scholar
  148. [177]177. Mamas M.A., Caldwell J.C., Chacko S., et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11:676-683. Go to Citation Crossref PubMed Google Scholar
  149. [179]179. Shelton R.J., Clark A.L., Goode K., et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart. 2009;95:924-930. Go to Citation Crossref PubMed Google Scholar
  150. [180]180. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. Go to Citation Crossref PubMed Google Scholar
  151. [182]182. Packer D.L., Mark D.B., Robb R.A., et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261-1274. Go to Citation Crossref PubMed Google Scholar
  152. [183]183. Vaduganathan M., Piccini J.P., Camm A.J., et al. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial. Eur J Heart Fail. 2022;24:1094-1101. Go to Citation Crossref PubMed Google Scholar
  153. [184]184. Kirchhof P., Camm A.J., Goette A., et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305-1316. Go to Citation Crossref PubMed Google Scholar
  154. [185]185. Rillig A., Magnussen C., Ozga A.K., et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation. 2021;144:845-858. Crossref PubMed Google Scholar a [...] reducing the risk of cardiovascular events. b [...] consisted mostly of HFpEF (56%) and HFmrEF.
  155. [186]186. Packer D.L., Piccini J.P., Monahan K.H., et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021;143:1377-1390. Go to Citation Crossref PubMed Google Scholar
  156. [187]187. Kotecha D., Bunting K.V., Gill S.K., et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA. 2020;324:2497-2508. Crossref PubMed Google Scholar a [...] of a beta-blocker, bisoprolol, to digoxin. b [...] and hypotension with beta-blockers.
  157. [189]189. Rush C.J., Berry C., Oldroyd K.G., et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1130-1143. Go to Citation Crossref PubMed Google Scholar
  158. [191]191. Hwang S.J., Melenovsky V., Borlaug B.A. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63:2817-2827. Go to Citation Crossref PubMed Google Scholar
  159. [193]193. Branch K.R., Probstfield J.L., Eikelboom J.W., et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation. 2019;140:529-537. Go to Citation Crossref PubMed Google Scholar
  160. [195]195. Herrscher T.E., Akre H., Øverland B., et al. High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function. J Card Fail. 2011;17:420-425. Go to Citation Crossref PubMed Google Scholar
  161. [196]196. Chan J., Sanderson J., Chan W., et al. Prevalence of sleep-disordered breathing in diastolic heart failure. Chest. 1997;111:1488-1493. Go to Citation Crossref PubMed Google Scholar
  162. [197]197. Bitter T., Faber L., Hering D., et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail. 2009;11:602-608. Go to Citation Crossref PubMed Google Scholar
  163. [199]199. Javaheri S., Barbe F., Campos-Rodriguez F., et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69:841-858. Go to Citation Crossref PubMed Google Scholar
  164. [200]200. Mehra R., Chung M.K., Olshansky B., et al. Sleep-disordered breathing and cardiac arrhythmias in adults: mechanistic insights and clinical implications: a scientific statement from the American Heart Association. Circulation. 2022;146:e119-e136. Go to Citation Crossref PubMed Google Scholar
  165. [201]201. Olson L.J., Somers V.K. Treating central sleep apnea in heart failure: outcomes revisited. Circulation. 2007;115:3140-3142. Go to Citation Crossref PubMed Google Scholar
  166. [202]202. Mehra R., Wang L., Andrews N., et al. Dissociation of objective and subjective daytime sleepiness and biomarkers of systemic inflammation in sleep-disordered breathing and systolic heart failure. J Clin Sleep Med. 2017;13:1411-1422. Crossref PubMed Google Scholar a [...] gasping, choking, or witnessed apneas. b [...] sensitivity as a trigger for testing.
  167. [205]205. Yoshihisa A., Suzuki S., Yamaki T., et al. Impact of adaptive servo-ventilation on cardiovascular function and prognosis in heart failure patients with preserved left ventricular ejection fraction and sleep-disordered breathing. Eur J Heart Fail. 2013;15:543-550. Go to Citation Crossref PubMed Google Scholar
  168. [206]206. D'Elia E., Ferrero P., Vittori C., et al. Beneficial effects of adaptive servo-ventilation on natriuretic peptides and diastolic function in acute heart failure patients with preserved ejection fraction and sleep-disordered breathing. Sleep Breath. 2019;23:287-291. Go to Citation Crossref PubMed Google Scholar
  169. [207]207. O'Connor C.M., Whellan D.J., Fiuzat M., et al. Cardiovascular outcomes with minute ventilation-targeted adaptive servo-ventilation therapy in heart failure: the CAT-HF trial. J Am Coll Cardiol. 2017;69:1577-1587. Crossref PubMed Google Scholar a [...] endpoints in those with HFpEF b [...] treatment for OSA or central sleep apnea.
  170. [208]208. Sánchez-de-la-Torre M., Sánchez-de-la-Torre A., Bertran S., et al. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Lancet Respir Med. 2020;8:359-367. Go to Citation Crossref PubMed Google Scholar
  171. [209]209. Cowie M.R., Woehrle H., Wegscheider K., et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095-1105. Go to Citation Crossref PubMed Google Scholar
  172. [211]211. Affas Z., Affas S., Tabbaa K. Continuous positive airway pressure reduces the incidence of atrial fibrillation in patients with obstructive sleep apnea: a meta-analysis and systematic review. Spartan Med Res J. 2022;7:34521. Go to Citation Crossref PubMed Google Scholar
  173. [212]212. Yumino D., Redolfi S., Ruttanaumpawan P., et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation. 2010;121:1598-1605. Go to Citation Crossref PubMed Google Scholar
  174. [213]213. Carneiro-Barrera A., Amaro-Gahete F.J., Guillén-Riquelme A., et al. Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity: the INTERAPNEA randomized clinical trial. JAMA Network Open. 2022;5:e228212. Go to Citation Crossref PubMed Google Scholar
  175. [214]214. Mokhlesi B., Ayas N.T. Cardiovascular events in obstructive sleep apnea - can CPAP therapy SAVE lives? N Engl J Med. 2016;375:994-996. Go to Citation Crossref PubMed Google Scholar
  176. [215]215. Bansal N., Katz R., Robinson-Cohen C., et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiol. 2017;2:314-318. Go to Citation Crossref PubMed Google Scholar
  177. [216]216. Vijay K., Neuen B.L., Lerma E.V. Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities. Cardiorenal Med. 2022;12:1-10. Go to Citation Crossref PubMed Google Scholar
  178. [217]217. Unger E.D., Dubin R.F., Deo R., et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18:103-112. Go to Citation Crossref PubMed Google Scholar
  179. [218]218. Khan Y.H., Sarriff A., Adnan A.S., et al. Chronic kidney disease, fluid overload and diuretics: a complicated triangle. PLoS One. 2016;11:e0159335. Go to Citation Crossref Google Scholar
  180. [219]219. Pocock S.J., Ariti C.A., McMurray J.J., et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404-1413. Go to Citation Crossref PubMed Google Scholar
  181. [220]220. Damman K., Valente M.A., Voors A.A., et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455-469. Go to Citation Crossref PubMed Google Scholar
  182. [221]221. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998-1005. Go to Citation Crossref PubMed Google Scholar
  183. [222]222. Georgiopoulou V.V., Velayati A., Burkman G., et al. Comorbidities, sociodemographic factors, and hospitalizations in outpatients with heart failure and preserved ejection fraction. Am J Cardiol. 2018;121:1207-1213. Go to Citation Crossref PubMed Google Scholar
  184. [223]223. Gergei I., Krämer B.K., Scharnagl H., et al. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction. Peptides. 2019;111:112-117. Go to Citation Crossref PubMed Google Scholar
  185. [224]224. Bansal N., Zelnick L.R., Ballantyne C.M., et al. Upper reference limits for high-sensitivity cardiac troponin T and N-terminal fragment of the prohormone brain natriuretic peptide in patients with CKD. Am J Kidney Dis. 2022;79:383-392. Go to Citation Crossref PubMed Google Scholar
  186. [225]225. Selvaraj S., Claggett B., Shah S.J., et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11:e005288. Go to Citation Crossref PubMed Google Scholar
  187. [226]226. Wannamethee S.G., Welsh P., Papacosta O., et al. Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease. Circ Heart Fail. 2014;7:732-739. Go to Citation Crossref PubMed Google Scholar
  188. [229]229. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860. Go to Citation Crossref PubMed Google Scholar
  189. [235]235. Mc Causland F.R., Lefkowitz M.P., Claggett B., et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020;142:1236-1245. Go to Citation Crossref PubMed Google Scholar
  190. [236]236. Trullàs J.C., Morales-Rull J.L., Casado J., et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44:5: 411-421. Go to Citation Crossref PubMed Google Scholar
  191. [237]237. Hossain M.Z., Chew-Graham C.A., Sowden E., et al. Challenges in the management of people with heart failure with preserved ejection fraction (HFpEF) in primary care: a qualitative study of general practitioner perspectives. Chronic Illn. 2022;18:410-425. Crossref PubMed Google Scholar a [...] to less consistency in GDMT prescription. b [...] uncertainty, and inequities in care.
  192. [238]238. Saxon D.T., Kennel P.J., Guyer H.M., et al. Specialty-based variability in diagnosing and managing heart failure with preserved ejection fraction. Mayo Clin Proc. 2020;95:669-675. Go to Citation Crossref PubMed Google Scholar
  193. [239]239. Lindberg F., Lund L.H., Benson L., et al. Patient profile and outcomes associated with follow-up in specialty vs. Primary care in heart failure. ESC Heart Fail. 2022;9:822-833. Go to Citation Crossref PubMed Google Scholar
  194. [240]240. Forsyth F., Brimicombe J., Cheriyan J., et al. Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis. BJGP Open. 2021;5:6: BJGPO.2021.0094. Go to Citation Crossref Google Scholar
  195. [241]241. Baumwol J. I Need Help"-a mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017;36:593-594. Go to Citation Crossref PubMed Google Scholar
  196. [242]242. Shah S.J. Why we should care about who cares for patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2022;15:e009867. Go to Citation Crossref Google Scholar
  197. [243]243. Maddox T.M., Januzzi J.L. Jr., Allen L.A., et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77:772-810. Go to Citation Crossref PubMed Google Scholar
  198. [244]244. Brush J.E. Jr., Handberg E.M., Biga C., et al. 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol. 2015;65:2118-2136. Crossref PubMed Google Scholar a [...] backgrounds should be viewed as an asset. b [...] for correcting identified deficiencies. c [...] given the high likelihood of polypharmacy.
  199. [245]245. Shah S.J., Cogswell R., Ryan J.J., et al. How to develop and implement a specialized heart failure with preserved ejection fraction clinical program. Curr Cardiol Rep. 2016;18:122. Crossref PubMed Google Scholar a [...] improve the care of individuals with HFpEF. b [...] the electronic health record) mechanisms.
  200. [246]246. Shah S.J., Kitzman D.W., Borlaug B.A., et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134:73-90. Go to Citation Crossref PubMed Google Scholar

200 of 203 shown

Cited by

Sorted by citations

Authors
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2023-05
Volume
81
Issue
18
Pages
1835-1878
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2023.03.393
OpenAlex
W4366371728
Cited by
554
References
42
Citations by year
2026: 162 · 2025: 194 · 2024: 137 · 2023: 60 · 2012: 1
FWCI
108.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
Keywords
heart failure with preserved ejection fraction, heart failure treatment, clinical decision pathway, expert consensus
MeSH terms
American Heart Association, Cardiology, Cardiovascular System, Heart Failure, Humans, United States, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review